RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
479 articles about RedHill Biopharma
-
RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2/23/2017
-
RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA Phase III Study For Acute Gastroenteritis
2/13/2017
-
RedHill Biopharma Release: Pharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
1/11/2017
-
RedHill Biopharma Release: Pharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
1/10/2017
-
RedHill Biopharma Announces YELIVA (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
1/6/2017
-
RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal
1/3/2017
-
RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIV For Multiple Myeloma
12/19/2016
-
RedHill Biopharma And IntelGenx Corp. Announce Definitive Agreement For Commercialization Of Rizaport For Migraines With Pharmatronic Co. In South Korea
12/14/2016
-
RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
12/13/2016
-
RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
12/12/2016
-
RedHill Biopharma Announces YELIVA (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
11/21/2016
-
RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 For H. pylori Infection Ahead Of Confirmatory Phase III Study
11/10/2016
-
RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA And Expected Timing Of Top-Line Results
11/3/2016
-
RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
11/3/2016
-
RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
11/2/2016
-
RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
10/18/2016
-
RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn’s Disease Program
10/6/2016
-
RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017
10/6/2016
-
RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA In Hepatocellular Carcinoma At Medical University of South Carolina
10/5/2016
-
RedHill Biopharma And IntelGenx Corp. Announce RIZAPORT Commercialization Term Sheet With Pharmatronic Co. For Korea
9/21/2016